Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Resignation and return to work in patients receiving allogeneic hematopoietic cell transplantation close up.
Kurosawa S, Yamaguchi T, Mori A, Matsuura T, Mori T, Tanaka M, Kondo T, Umemoto Y, Goto H, Yoshioka S, Machida S, Sato T, Katayama Y, Kato S, Shono K, Mizuno I, Fujiwara SI, Kohno A, Takahashi M, Fukuda T. Kurosawa S, et al. Among authors: shono k. J Cancer Surviv. 2022 Oct;16(5):1004-1015. doi: 10.1007/s11764-021-01092-w. Epub 2021 Aug 27. J Cancer Surviv. 2022. PMID: 34449050
Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.
Yano S, Mori T, Kanda Y, Kato J, Nakaseko C, Fujisawa S, Tomita N, Sakai R, Shono K, Saitoh T, Aotsuka N, Kobayashi N, Saito T, Takahashi S, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Yano S, et al. Among authors: shono k. Bone Marrow Transplant. 2015 Oct;50(10):1299-305. doi: 10.1038/bmt.2015.158. Epub 2015 Jul 13. Bone Marrow Transplant. 2015. PMID: 26168068
Effect of the order of TBI and cyclophosphamide administration on the outcome of allogeneic hematopoietic stem cell transplantation.
Motohashi K, Fujisawa S, Onizuka M, Kako S, Sakaida E, Shono K, Tatara R, Doki N, Mori T, Sakura T, Aotsuka N, Fuji E, Tomita N, Kawai N, Saitoh T, Usuki K, Taguchi J, Watanabe R, Kobayashi S, Yano S, Kanamori H, Takahashi S, Okamoto S. Motohashi K, et al. Among authors: shono k. Bone Marrow Transplant. 2015 Nov;50(11):1476-9. doi: 10.1038/bmt.2015.142. Epub 2015 Jul 20. Bone Marrow Transplant. 2015. PMID: 26191948 No abstract available.
Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.
Kurosawa S, Yamaguchi H, Yamaguchi T, Fukunaga K, Yui S, Wakita S, Kanamori H, Usuki K, Uoshima N, Yanada M, Shono K, Ueki T, Mizuno I, Yano S, Takeuchi J, Kanda J, Okamura H, Inamoto Y, Inokuchi K, Fukuda T. Kurosawa S, et al. Among authors: shono k. Biol Blood Marrow Transplant. 2016 Jun;22(6):1125-1132. doi: 10.1016/j.bbmt.2016.03.015. Epub 2016 Mar 31. Biol Blood Marrow Transplant. 2016. PMID: 27040395 Free article.
D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
Yui S, Kurosawa S, Yamaguchi H, Kanamori H, Ueki T, Uoshima N, Mizuno I, Shono K, Usuki K, Chiba S, Nakamura Y, Yanada M, Kanda J, Tajika K, Gomi S, Fukunaga K, Wakita S, Ryotokuji T, Fukuda T, Inokuchi K. Yui S, et al. Among authors: shono k. Ann Hematol. 2017 Oct;96(10):1641-1652. doi: 10.1007/s00277-017-3074-y. Epub 2017 Jul 31. Ann Hematol. 2017. PMID: 28762080 Clinical Trial.
Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia.
Sakaguchi M, Yamaguchi H, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Gomi S, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Nakajima N, Marumo A, Omori I, Fujiwara Y, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi K. Sakaguchi M, et al. Among authors: shono k. Blood Adv. 2018 Oct 23;2(20):2744-2754. doi: 10.1182/bloodadvances.2018020305. Blood Adv. 2018. PMID: 30341082 Free PMC article.
Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation.
Shimizu R, Takeuchi M, Sakaida E, Ohwada C, Toyosaki M, Machida S, Onizuka M, Shono K, Onoda M, Saito T, Yano S, Tanaka M, Fujisawa S, Mori T, Usuki K, Takahashi S, Kanamori H, Nakaseko C, Okamoto S. Shimizu R, et al. Among authors: shono k. Ann Hematol. 2019 Jul;98(7):1781-1783. doi: 10.1007/s00277-019-03717-8. Epub 2019 May 22. Ann Hematol. 2019. PMID: 31119366 No abstract available.
Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis.
Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Matsumoto K, Aotsuka N, Goto M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study; Group for Cell Therapy (KSGCT). Tachibana T, et al. Among authors: shono k. Leukemia. 2019 Nov;33(11):2610-2618. doi: 10.1038/s41375-019-0494-9. Epub 2019 May 30. Leukemia. 2019. PMID: 31147621
Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia.
Sakaguchi M, Yamaguchi H, Kuboyama M, Najima Y, Usuki K, Ueki T, Oh I, Mori S, Kawata E, Uoshima N, Kobayashi Y, Kako S, Tajika K, Shono K, Kayamori K, Hagihara M, Kanda J, Uchiyama H, Kuroda J, Uchida N, Kubota Y, Kimura S, Kurosawa S, Date K, Nakajima N, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Wakita S, Arai K, Kitano T, Kakihana K, Kanda Y, Ohashi K, Fukuda T, Inokuchi K. Sakaguchi M, et al. Among authors: shono k. Int J Hematol. 2019 Nov;110(5):566-574. doi: 10.1007/s12185-019-02720-z. Epub 2019 Aug 20. Int J Hematol. 2019. PMID: 31432396
107 results